Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AbundRX vs Enhance MD

AbundRX
Graded #193

Lower grade

vs+18.5
Enhance MD
Graded #11

Higher grade

The verdict

Enhance MD takes it — 84.8/100 to 66.3/100.

Enhance MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A transparently tiered compounded program — semaglutide $212/mo (first month $112), tirzepatide $280, a $169 microdose, and a $322 combo — backed by six-month lab testing and provider care, with NAD+ on the side.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEnhance MD +16
66
82
Dose & formulationEnhance MD +18
64
82
Clinical oversightEnhance MD +9
79
88
Labs & monitoringEnhance MD +37
53
90
FulfillmentEnhance MD +10
74
84
Contract termsEnhance MD +29
55
84
AbundRX · left barEnhance MD · right bar

The numbers

MetricAbundRXEnhance MD
WeighScore66.3/10084.8/100
GradeCB
Scorecard rank#193#11
Semaglutide$179/mo (compounded)$212/mo
Tirzepatide$279/mo (compounded)$280/mo
CoverageCoverage not publishedNot publicly listed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
AbundRX

Graded #193 · C

Strengths

  • Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
  • Fast, free shipping and a simple few-minute online health assessment
  • Provider-guided care connecting patients with licensed US clinicians
  • Publishes Terms, Privacy, and Refund policies

Where it loses points

  • Claims LegitScript certification in text but displays no verifiable seal or listing
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Compounding pharmacy not named; no HIPAA notice found; state availability not published
  • Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
Enhance MD

Graded #11 · B

Strengths

  • Transparent tiered pricing across sema, tirz, microdose, and combo
  • Dose-flat — the price does not step up as you titrate
  • Six-month lab testing plus provider-led care
  • NAD+ longevity adjacency available

Where it loses points

  • Compounded only — no brand-name Ozempic/Wegovy or Mounjaro/Zepbound
  • No oral or sublingual route
  • States served are not published
  • Higher entry price than the cheapest compounded programs

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard